Yahoo
HKSE - Delayed Quote HKD

Hua Medicine (Shanghai) Ltd. (2552.HK)

2.170 -0.005 (-0.23%)
At close: 4:08:13 PM GMT+8

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
Name Title Pay Exercised Year Born
Dr. Li Chen Ph.D.
Founder, CEO, Member of Portfolio Advisory Board & Executive Director 11.96M -- 1963
Dr. Yi Zhang M.D., Ph.D.
Senior VP of Pharma Development, Chief Medical Officer – China and Executive Director 5.46M -- 1975
Mr. Chien Cheng Lin J.D.
Executive VP, Chief Strategy Officer & Executive Director 6.69M -- 1971
Dr. Fuxing Tang Ph.D.
CTO, VP of Chemical Manufacturing Control Department and Head of R&D in USA -- -- 1967
Dr. Changhong Li Ph.D.
Chief Scientific Officer -- -- 1970
Mr. Chengde Wang
Head of IR -- -- 1948
Mr. Yu Lu
Vice President of Sales & Marketing -- -- 1975
Mr. Ying Xie M.B.A.
VP of Quality Assurance Division & Chief Quality Officer -- -- 1980
Ms. Nelly Au-Yeung
Company Secretary -- -- --

Hua Medicine (Shanghai) Ltd.

Hua Medicine, Building 2, Lane 36
Xuelin Road Pudong New Area
Shanghai, 201203
China
86 21 3810 1800 https://www.huamedicine.com
Sector: 
Healthcare
Full Time Employees: 
424

Description

Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination with GLP1RA and small molecule GLP-1 for T2D and obesity; combination with insulin to treat insulin sparing in T2D; second generation glucokinase (GK) inhibitor and GK NAM for metabolic disease; mGLUR5 negative allosteric modulator (NAM) for PD-LID and drug addiction; and Dorzagliatin for the treatment of T2D-Drug Naïve, T2D-Metformin Tolerated, RWE study for Diabetes Remission, MODY-2, Diabetes prevention IGT2NGT, Frailty, Early AD, and CFRD. Hua Medicine (Shanghai) Ltd. was incorporated in 2011 and is headquartered in Shanghai, China.

Corporate Governance

Hua Medicine (Shanghai) Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: